European Patent Office issued its intention to grant Genervon Biopharmaceuticals a European patent on Methods of Treating Neuronal Disorders using MNTF peptides and analogs thereof.

Pasadena, USA, December 17, 2012 – The European Patent Office notified Genervon of its intention to grant a European patent on Methods of Treating Neuronal Disorders using MNTF peptides and analogs thereof. Genervon will proceed to have the patents for EPO application No. 07867451.2 issued and bring the portfolio of Genervon’s issued Composition of Matters and Use patents to 46.

This patent will grant the intellectual property rights to the use of GM600 in the preparation of a medicament for the therapeutic treatment of neuronal diseases and disorders including stroke, cerebral ischemia, spinal cord injuries (SCI), Huntington’s disease (HD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease by intravenous delivery.

Genervon has discovered a novel endogenous embryonic stage family of 9 human Master Regulators of the Nervous System. The company has developed one of the Master Regulator named GM600, for disease modification in neurodegenerative diseases and for neuroprotection. A Phase 1 clinical trial in human volunteers by bolus intravenous administration was completed and GM600 is very safe and tolerable at very high multiple doses. A GM600 serial number is assigned to each indication. GM602 and GM608 are assigned to ischemic stroke and Parkinson’s disease, respectively, which are in Phase 2 Clinical Trials. GM604 is assigned to ALS indication, with promising and comprehensive mechanisms of actions.

GM600 provided neuroprotection against soluble inflammatory factors from CNS human patients’ Cerebral Spinal Fluid (CSF) in vitro by the following percent increase of neuronal cells: Stroke (205%), ALS (175%), MS (246%), AD (191%), HD (271%), PD (198%). GM600 has shown very efficacious effects in animal models in many neurodegenerative and acute injuries models.

The discovery of endogenous embryonic stage human master regulators is changing the drug development paradigm from hitting single gene/pathway to a comprehensive and dynamic multi-factorial approach to treat the complex neuro-degenerative diseases. Genervon is at the forefront of a drug development paradigm shift that is beginning to be appreciated.

Genervon Biopharmaceuticals, LLC ( is an innovative clinical stage biopharmaceutical company providing breakthrough biological drugs for some of the world’s critical unmet medical needs.


Source: Genervon Biopharmaceuticals

0 Condivisioni